Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose versus two-dose dalbavancin for acute bacterial skin and skin structure infections
2014-000419-15Phase 3Completed
- Sponsor
- Durata Therapeutics
- Start
- Jul 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI) and bacterial infections of skin and subcutaneous tissue (SSTI) (2 arms), sponsored by Durata Therapeutics. Primary endpoint: Clinical response at 48-72 hours. Started Jul 2014; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)bacterial infections of skin and subcutaneous tissue (SSTI)
Beyond the preview
Go deeper on 2014-000419-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000419-15.